BRIEF-Regulus Therapeutics q2 loss per share $0.40
August 02, 2016 at 16:59 PM EDT
* On track to deliver follow-up results from rg-101 studies while working to address deficiencies outlined in by fda
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.